Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Pharmaceuticals Holding Co. is conducting a Phase I clinical study titled ‘A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors.’ The study aims to assess the safety and tolerability of SPH5030 tablets in patients with HER2-positive advanced solid tumors, a significant area of research given the aggressive nature of these cancers.
The intervention being tested is the SPH5030 tablet, an experimental drug administered orally to patients. The purpose of this drug is to treat HER2-positive advanced solid tumors, with patients receiving varying doses to determine optimal safety and effectiveness.
This interventional study follows a single-group assignment model without masking, focusing primarily on treatment. Participants are allocated to receive one of five different doses of SPH5030 tablets, taken once or twice daily.
The study began on February 8, 2022, with primary completion expected soon, and the last update was submitted on August 15, 2025. These dates are crucial as they indicate the study’s progress and potential upcoming results.
The market implications of this study are significant for Shanghai Pharmaceuticals, as positive results could enhance their stock performance and investor confidence. Given the competitive landscape of cancer treatments, successful outcomes could position the company favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.